Johnson and Johnson 2014 Annual Report Download - page 15

Download and view the complete annual report

Please find page 15 of the 2014 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 84

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84

Pharmaceutical Segment
The Pharmaceutical segment achieved sales of $32.3 billion in 2014, representing an increase of 14.9% over the prior
year, with strong operational growth of 16.5% and a negative currency impact of 1.6%. U.S. sales were $17.4 billion, an
increase of 25.0%. International sales were $14.9 billion, an increase of 5.0%, which included 8.3% operational growth
and a negative currency impact of 3.3%. In 2013, Pharmaceutical segment sales included a positive adjustment to
previous estimates for Managed Medicaid rebates. This negatively impacted 2014 Pharmaceutical operational sales
growth by 0.8% as compared to the prior year. In 2014, sales of the Company’s Hepatitis C products,
OLYSIO®/SOVRIAD®(simeprevir) and INCIVO®(telaprevir), had a positive impact of 6.9% on the operational growth of
the Pharmaceutical segment.
Major Pharmaceutical Therapeutic Area Sales:*
% Change
(Dollars in Millions) 2014 2013 2012 ’14 vs. ’13 ’13 vs. ’12
Total Immunology $10,193 9,190 7,874 10.9% 16.7
REMICADE®6,868 6,673 6,139 2.9 8.7
SIMPONI®/SIMPONI ARIA®1,187 932 607 27.4 53.5
STELARA®2,072 1,504 1,025 37.8 46.7
Other Immunology 66 81 103 (18.5) (21.4)
Total Infectious Diseases 5,599 3,550 3,194 57.7 11.1
EDURANT®365 236 102 54.7 **
INCIVO®226 517 443 (56.3) 16.7
OLYSIO®/SOVRIAD®2,302 23 – ** –
PREZISTA®1,831 1,673 1,414 9.4 18.3
Other Infectious Diseases 875 1,101 1,235 (20.5) (10.9)
Total Neuroscience 6,487 6,667 6,718 (2.7) (0.8)
CONCERTA®/methylphenidate 599 782 1,073 (23.4) (27.1)
INVEGA®640 583 550 9.8 6.0
INVEGA®SUSTENNA®/XEPLION®1,588 1,248 796 27.2 56.8
RISPERDAL®CONSTA®1,190 1,318 1,425 (9.7) (7.5)
Other Neuroscience 2,470 2,736 2,874 (9.7) (4.8)
Total Oncology 4,457 3,773 2,629 18.1 43.5
VELCADE®1,618 1,660 1,500 (2.5) 10.7
ZYTIGA®2,237 1,698 961 31.7 76.7
Other Oncology 602 415 168 45.1 **
Total Other 5,577 4,945 4,936 12.8 0.2
PROCRIT®/EPREX®1,238 1,364 1,462 (9.2) (6.7)
XARELTO®1,522 864 239 76.2 **
Other 2,817 2,717 3,235 3.7 (16.0)
Total Pharmaceutical Sales $32,313 28,125 25,351 14.9% 10.9
* Prior year amounts have been reclassified to conform to current year presentation.
** Percentage greater than 100%
Immunology products achieved sales of $10.2 billion in 2014, representing an increase of 10.9% as compared to the prior
year. The increased sales of STELARA®(ustekinumab) and SIMPONI®/SIMPONI ARIA®(golimumab) were primarily due
to market growth and market share gains. REMICADE®(infliximab) growth was primarily due to market growth.
The patents for REMICADE®in certain countries in Europe (Germany, Spain, United Kingdom, Sweden, Austria, Belgium,
Switzerland, Denmark, France, Greece, Italy, Luxembourg and the Netherlands) expire in February 2015. Loss of exclusivity
will likely result in a reduction in sales as biosimilar versions are introduced to the market. See Note 21 to the
Consolidated Financial Statements for legal matters regarding the REMICADE®patents.
Johnson & Johnson 2014 Annual Report •5